EVOTEC SE INH
Commented by André Will-Laudien on October 29th, 2026 | 05:39 CET
Life Sciences in Focus as Sector Rotation Takes Shape: Bayer, Vidac Pharma, Eli Lilly, Novo Nordisk and Evotec in 2027
AI is consolidating, and the Life Sciences sector is firing up its first turbo: Rising healthcare spending, the demographic ageing wave and a veritable wave of innovation are catapulting the industry straight into a multi-year supercycle – and now the major players are reallocating their capital. AI and high-tech have delivered their returns, and now the new outperformers for 2027 are stepping into the spotlight. The catch: after years of heavy losses, most stocks are trading close to their 5-year lows. That will not last! Some companies are already waiting in the wings, with the painful restructuring completed. Leading the way, Novo Nordisk continues its relentless advance as the undisputed flagship of the global obesity and diabetes wave. A genuine hidden gem for return hunters is Vidac Pharma. Through its research into the Warburg effect, the biotech firm is revolutionising cancer therapy and, as a classic high-beta play, adds a dash of spice to opportunity-focused portfolios. The giant Bayer is also back, consistently using the current valuation lull as a major entry opportunity to ignite the next phase of growth with a revamped pipeline. The power quartet is completed by Hamburg-based drug discovery company Evotec, which benefits directly from demand for complex therapies as an indispensable infrastructure and development partner. Those who want to stay ahead in the coming Life Sciences boom need to set the course for their portfolio now!
Read
Commented by Fabian Lorenz on October 23rd, 2026 | 05:38 CEST
Strong News and Buy Recommendations: Vonovia, Evotec and Lahontan Gold
Strong news from Lahontan Gold. The explorer has published a positive preliminary economic assessment (PEA) for its Santa Fe gold-silver project in Nevada. The after-tax net present value stands at approximately USD 820 million, significantly exceeding the company's current market capitalisation. The company is also working to expand the resource base. While Lahontan Gold shareholders can look forward to the approaching start of gold production, Vonovia shareholders face an uncertain future. The expropriation scenario is weighing on sentiment. Even JPMorgan's assessment that these concerns are exaggerated does little to change the picture. In a worst-case scenario, the German government would intervene. And what about Evotec? The shares have gained more than 10% in recent trading days. The appointment of a new executive at Novo Nordisk could inject fresh momentum into the company.
Read
Commented by Stefan Bode on October 20th, 2026 | 05:31 CEST
Turnaround Opportunities and Share Price Shocks: Almonty Industries, Evotec and PNE Put to the Test
Today's commentary deals with an operational turning point, geopolitical realignment and severe setbacks. While a struggling drug discovery company fights to find a bottom with surprising quarterly figures, a Western raw materials producer benefits from a geopolitical break with former monopoly suppliers. Meanwhile, a drastic profit warning in the renewable energy sector plunges investors into a deep crisis of confidence. This market report analyses which technical hurdles now matter and where genuine opportunities lie despite high volatility.
Read
Commented by Fabian Lorenz on October 15th, 2026 | 05:25 CEST
Nel ASA and Evotec Shares Rise! When Will DRC Gold Take Off?
Evotec shares gained more than 9% yesterday, driven by better-than-expected figures for the first nine months. In an initial reaction, analysts once again recommended buying the stock. Nel ASA has also received positive news in recent days. The Norwegian company secured an order in the United States, while its collaboration with Rheinmetall is also attracting attention. The aim is to jointly develop solutions for local production of low-emission fuels, particularly for the defence sector and critical infrastructure. Could DRC Gold shares be poised for a breakout? The company, led by a German CEO, aims to establish itself in one of Africa's most historic gold-producing regions. It recently reached an important milestone. The aim is to bring the Kebigada deposit, with a historical resource estimate of around 4.1 million ounces of gold, into production as quickly as possible. Further acquisitions are also under consideration.
Read
Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST
Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!
New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?
Read
Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST
BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk
The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.
Read
Commented by Carsten Mainitz on October 7th, 2026 | 08:40 CEST
Spot the Next Stock Catalyst Early: Key Milestones for Lahontan Gold, Evotec and Deutz
Get in before the stock takes off! The key is to identify the trigger for the next share-price move early enough. Lahontan Gold is working to restart a historic gold mine in Nevada and recently made an attractive acquisition. Biotech company Evotec is fighting to turn its operations around and rebuild investor confidence. Deutz is expanding its industrial business into energy and defense, taking the company into new dimensions of growth. What does this mean for investors? Where are the most compelling opportunities for stock pickers?
Read
Commented by Matthias Schomber on October 1st, 2026 | 07:55 CEST
Evotec, DroneShield and Power Metallic Mines: Turnaround Opportunities, Defence Boom and Commodities Hidden Gem
The stock market can be a madhouse at the best of times—and right now, some developments seem to defy all logic. Yet markets are rarely driven by fundamentals alone. Greed, fear and shifting investor sentiment can send stocks in directions that appear difficult to explain from a purely rational perspective. While the cards are being reshuffled at Evotec's modern laboratories following a management shakeup, DroneShield is looking to benefit from the new defence boom in the skies. In Canada, Power Metallic Mines sits on a vast polymetallic deposit. Each of the three stocks has its own technical chart setup. We examine the hard facts, look at margins and balance sheets, and assess the real opportunities. Which of these three stocks offers significant turnaround potential, and where do risks still loom? Read on to find out.
Read
Commented by Fabian Lorenz on September 22nd, 2026 | 07:45 CEST
Analysts See Multibagger Potential: Nordex, Evotec and Aspermont
Analysts see multibagger potential in Aspermont's stock. The Australian company appears to be making good progress in its transformation from a specialist publisher into a scalable provider of data and analytics for the global resources industry. The stock has yet to take off. Its 2028 P/E ratio is below 10. Nordex is no longer a bargain. Analysts see further growth opportunities, but the stock has already priced in much of that potential. Nevertheless, analysts recommend buying the shares. The US business is becoming increasingly important. Buying Evotec shares is not an obvious choice right now. The stock has fallen below EUR 3, while positive company news is being ignored by the market. Could this perhaps be an opportunity?
Read
Commented by Armin Schulz on September 21st, 2026 | 07:30 CEST
Novo Nordisk, BioNxt Solutions, Evotec: When Injections Become Pills, The Cash Starts Rolling In
The daily injection has had its day. For a long time, taking biologics in pill form was considered a pipe dream, but as of this year, it is becoming a billion-dollar business. On September 17, 2026, Novo Nordisk announced a partnership with Orbis Medicines worth up to USD 1.4 billion to make injections available orally. In February, the Danish company secured a partnership with Vivtex worth up to USD 2.1 billion. Whoever can deliver peptides through the stomach could see the industry come knocking. We are taking a closer look at Novo Nordisk, BioNxt Solutions and Evotec, which cover the entire spectrum of this trend—from acquisitions to technology to development.
Read